Lexaria Bioscience (LEXX) Projected to Announce Quarterly Earnings on Monday

Lexaria Bioscience (NASDAQ:LEXX) is anticipated to post its Q3 2026 results before the market opens on Monday, July 13th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.05 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Friday, July 17, 2026 at 12:30 PM ET.

Lexaria Bioscience (NASDAQ:LEXX) last posted its earnings results on Monday, April 13th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.05 million. On average, analysts expect Lexaria Bioscience to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Lexaria Bioscience Stock Performance

LEXX opened at $0.56 on Monday. The company’s 50 day moving average is $0.63 and its 200-day moving average is $0.71. The company has a market cap of $13.88 million, a P/E ratio of -1.19 and a beta of 0.34. Lexaria Bioscience has a 1-year low of $0.46 and a 1-year high of $1.55.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded Lexaria Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $1.50.

Hedge Funds Weigh In On Lexaria Bioscience

An institutional investor recently bought a new stake in Lexaria Bioscience stock. Virtu Financial LLC bought a new position in Lexaria Bioscience Corp. (NASDAQ:LEXX) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 29,360 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned about 0.13% of Lexaria Bioscience as of its most recent SEC filing. 13.06% of the stock is owned by institutional investors.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.